Inhibitions of human parainfluenza virus type 2 replication by ribavirin and mycophenolate mofetil are restored by guanosine and <i>S</i>-(4-nitrobenzyl)-6-thioinosine

Abstract

Human parainfluenza virus type 2 (hPIV-2) is one of the major human respiratory tract pathogens of infants and children. hPIV-2 is a member of the genus Rubulavirus in the family Paramyxoviridae, and it possesses a single-stranded, non-segmented, negative stranded RNA genome of 15,654 nucleotides (1). hPIV-2 has 7 Summary The antiviral activities of a nucleoside analog antiviral drug (ribavirin) and a non-nucleoside drug (mycophenolate mofetil) against human parainfluenza virus type 2 (hPIV-2) were investigated, and the restoration of the inhibition by guanosine and S-(4-nitrobenzyl)-6thioinosine (NBTI: equilibrative nucleoside transporter 1 inhibitor) were also investigated. Ribavirin (RBV) and mycophenolate mofetil (MMF) inhibited cell fusion induced by hPIV-2. Both RBV and MMF considerably reduced the number of viruses released from the cells. Virus genome synthesis was inhibited by RBV and MMF as determined by polymerase chain reaction (PCR) and real time PCR. mRNA syntheses were also reduced. An indirect immunofluorescence study showed that RBV and MMF largely inhibited viral protein syntheses. Using a recombinant green fluorescence protein (GFP)-expressing hPIV-2 without matrix protein (rhPIV-2ΔMGFP), it was found that virus entry into the cells and multinucleated giant cell formation were almost completely blocked by RBV and MMF. RBV and MMF did not disrupt actin microfilaments or microtubules. Both guanosine and NBTI completely or partially reversed the inhibition by RBV and MMF in the viral replication, syntheses of genome RNA, mRNA and protein, and multinucleated giant cell formation. NBTI caused a little damage in actin microfilaments, but had no effect on microtubules. Both RBV and MMF inhibited the replication of hPIV-2, mainly by inhibiting viral genome RNA, mRNA and protein syntheses. The inhibition was almost completely recovered by guanosine. These results indicate that the major mechanism of the inhibition is the depletion of intracellular GTP pools.

Detected SARS-CoV-2 in Ascitic Fluid Followed by Cryptococcemia: a Case Report

“…In the case of solid organ transplant patients, chronic immunosuppressive therapy impairs T cell immunity [ 2 ], and disruption in viral control may lead to higher rates of viral replication [ 3 , 13 ]. While this could have contributed to a disseminated, more severe infection in this patient, viral RNA has been detected in blood samples from critically ill, immunocompetent patients as well [ 14 ].…”

COVID-19 in kidney transplant recipients

“…Based on this assumption, antimetabolite therapy was stopped in all patients. 17 The decision whether to hold CNI was based on clinical parameters. Two patients who were critically ill in the ICU eventually had CNI held.…”

The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

“…The anti-viral effect against all these numerous viruses mentioned above appears to be due to the reduction of GMP cell pool, whereas and it can be reversible with the addiction of guanosine in a dose dependent manner [154,155]. Similarly, MMF inhibits viral RNA, mRNA protein synthesis, and it almost completely blocks virus entry and cytopathic effect of human parainfluenza virus type 2 (hPIV-2), but these restrictions are recovered by guanosine and S-(4-nitrobenzyl)-6-thioinosine administration [156]. The only evidence of the presence of another antiviral mechanism of MMF derives from a study on hepatitis C virus (HCV).…”